The ERK5 pathway in BRAFV600E melanoma cells plays a role in development of acquired resistance to dabrafenib but not vemurafenib
FEBS Letters · 2024
DOI: 10.1002/1873-3468.14960 ↗Kurz gefasst
Fachartikel in der Zeitschrift FEBS Letters, 2024. Verfasst von Anil Kumar Mondru und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, UK. Hauptthemen laut MEDLINE: Oximes, Proto-Oncogene Proteins B-raf, Melanoma, Imidazoles. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: North West Cancer Research, Skin Cancer Research Fund, Wellcome Trust Institutional Strategic Support Fund.
Abstract (Originalsprache)
Malignant melanoma, an aggressive skin cancer with a poor prognosis, frequently features BRAFV600E mutation resulting in activation of the MAPK pathway and melanocyte proliferation and survival. BRAFV600E inhibitors like vemurafenib and dabrafenib have enhanced patient survival, yet drug resistance remains a significant challenge. We investigated the role of the ERK5 pathway in BRAFV600E melanoma cells and cells with acquired resistance to PLX4720 (vemurafenib) and dabrafenib. In BRAFV600E melanoma, ERK5 inhibition minimally affected viability compared to ERK1/2 inhibition. In vemurafenib‐resistant cells, ERK5 inhibition alone didn't impact viability or restore drug sensitivity to vemurafenib. However, in dabrafenib‐resistant cells, ERK5 inhibition reduced viability and enhanced the anti‐proliferative effect of MEK1/2 inhibition. Targeting the ERK5 pathway may represent a therapeutic opportunity in dabrafenib‐resistant melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, UK.
- Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, UK.
ORCID-Profile: Michael J Cross
Förderung
- North West Cancer Research
- Skin Cancer Research Fund
- Wellcome Trust Institutional Strategic Support Fund
- Qassim University
- Ministry of Education, Government of Saudi Arabia
Zitieren
APA
Mondru, A. K., Wilkinson, B., Aljasir, M. A., Alrumayh, A., Greaves, G., Emmett, M., Albohairi, S., Pritchard-Jones, R., & Cross, M. J. (2024). The ERK5 pathway in BRAFV600E melanoma cells plays a role in development of acquired resistance to dabrafenib but not vemurafenib. FEBS Letters. https://doi.org/10.1002/1873-3468.14960
Vancouver
Mondru AK, Wilkinson B, Aljasir MA, Alrumayh A, Greaves G, Emmett M, et al. The ERK5 pathway in BRAFV600E melanoma cells plays a role in development of acquired resistance to dabrafenib but not vemurafenib. FEBS Letters. 2024. doi:10.1002/1873-3468.14960
BibTeX
@article{Mondru2024,
author = {Mondru, Anil Kumar and Wilkinson, Beth and Aljasir, Mohammad A and Alrumayh, Ahmed and Greaves, Georgia and Emmett, Maxine and Albohairi, Saad and Pritchard-Jones, Rowan and Cross, Michael J},
title = {The ERK5 pathway in BRAFV600E melanoma cells plays a role in development of acquired resistance to dabrafenib but not vemurafenib},
journal = {FEBS Letters},
year = {2024},
doi = {10.1002/1873-3468.14960}
}
EUVIMED